Transplant Diagnostics Market Status and Trend Report By 2024Posted by Nicky Arora on March 26th, 2020 The global transplant diagnostics market size is expected to reach USD 895.2 million by 2024, according to a new report by Grand View Research, Inc. It is projected to expand at a CAGR of 7.6% over the forecast period. Increasing number of patients suffering from chronic diseases frequently leading to organ failure is creating an upsurge in demand for transplant procedures. In addition, adoption of stem cell therapy and personalized medicine is escalating, thereby influencing demand for transplant diagnostics. Risks and complexities associated with organ transplants necessitate the need for improved and sophisticated diagnostic tools. Next-Generation Sequencing (NGS) technology is rapidly replacing traditional diagnostic methods, such as serological techniques employed in Human Leukocyte Antigen (HLA) typing, owing to growing demand for high-throughput diagnostic tools with enhanced accuracy. Market growth is expected to be restrained by factors such as reimbursement controversies and ethical issues in some parts of the world. In addition, high cost of performing HLA matching using Polymerase Chain Reaction (PCR) and NGS devices is challenging the growth of the transplant diagnostics market in developing countries. Access Full Info @ https://www.grandviewresearch.com/industry-analysis/transplant-diagnostic-market/request/rs1 Further key findings from the study suggest:
Some major players in this market are Thermo Fisher Scientific, Inc.; Illumina, Inc.; F.Hoffmann La-Roche AG.; Abbott Laboratories, Inc.; Qiagen N.V.; Immucor Transplant Diagnostics, Inc.; Bio-Rad Laboratories, Inc.; Affymetrix, Inc.; and Omixon Ltd. Like it? Share it!More by this author |